Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

被引：48
|
作者：
Li, Qiao [1 ]
Quan, Lina [1 ]
Lyu, Jiankun [1 ]
He, Zenghui [1 ]
Wang, Xia [1 ]
Meng, Jiajia [1 ]
Zhao, Zhenjiang [1 ]
Zhu, Lili [1 ]
Liu, Xiaofeng [1 ]
Li, Honglin [1 ]
机构：
[1] East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China
来源：
ONCOTARGET | 2016年 / 7卷 / 40期
基金：
中国国家自然科学基金;
关键词：
immunotherapy; human programmed death 1; peptide inhibitor; protein-protein interactions (PPIs); de novo peptide design; CANCER-IMMUNOTHERAPY; HOT-SPOTS; WEB SERVER; BINDING; LIGANDS; ENERGY; DETERMINANTS; SIMULATION; EXPRESSION; PREDICTION;
D O I：
10.18632/oncotarget.11274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Blocking the interaction of human programmed death 1 (hPD-1) and its ligand hPD-L1 has been a promising immunotherapy in cancer treatment. In this paper, using a computational de novo peptide design method, we designed several hPD-1 binding peptides. The most potent peptide Ar5Y_4 showed a KD value of 1.38 +/- 0.39 mu M, comparable to the binding affinity of the cognate hPD-L1. A Surface Plasmon Resonance (SPR) competitive binding assay result indicated that Ar5Y_4 could inhibit the interaction of hPD-1/hPD-L1. Moreover, Ar5Y_4 could restore the function of Jurkat T cells which had been suppressed by stimulated HCT116 cells. Peptides described in this paper provide promising biologic candidates for cancer immunotherapy or diagnostics.
引用
收藏
页码：64967 / 64976
页数：10
相关论文
共 50 条
  • [21] Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics
    Cassol, Clarissa A.
    Owen, Dwight
    Kendra, Kari
    Braga, Juarez R.
    Frankel, Wendy L.
    Arnold, Christina A.
    HISTOPATHOLOGY, 2020, 77 (02) : 240 - 249
  • [22] Discovery of a macrocyclic peptide inhibitor of programmed death-ligand 1 (PD-L1)
    Scola, Paul
    Gillis, Eric
    Boy, Kenneth
    Langley, David
    Donnelly, David
    Miller, Michael
    Lombardo, Louis
    Poss, Michael
    Mapelli, Claudio
    Gillman, Kevin
    Yeung, Kap-Sun
    Sun, Li-Qiang
    Grant-Young, Katherine
    Allen, Martin
    Poirier, Maude
    Bowsher, Michael
    Zhu, Juliang
    Li, Ling
    Lafont, Virginie
    Sanghvi, Nashith
    Yan, Chunhong
    Easter, John
    Lee, Ving
    Zhang, Yunhui
    Goodrich, Jason
    Bonacorsi, Samuel
    Cole, Erin
    Mull, Eric
    Mathur, Arvind
    Kempson, James
    Wu, Dauh-Rurng
    Zhao, Qian
    Wichroski, Michael
    Campellone, Shalyn
    Loubeau, Martine
    Cockett, Mark
    Gao, Mian
    Korman, Alan
    Selby, Mark
    Wang, Ying-Kai
    Chauhan, Vibha
    Reid, Patrick
    Nishikawa, Junichi
    Goto, Hiroko
    Logan, Randall
    Cutrone, Jenny
    Denton, Rex
    Haskell, Roy
    Johnson, Kim
    Benitex, Yulia
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [23] In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
    Reddy, Vishwanatha R. A. P.
    Mwangi, William
    Sadigh, Yashar
    Nair, Venugopal
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [24] Corticosteroids and risk of hospitalization for infection among cancer patients treated with programmed cell death receptor/ligand 1 (PD-1/PD-L1) inhibitors
    Sorup, Signe
    Darvalics, Bianka
    Russo, Leo
    Oksen, Dina
    Lamy, Francois-Xavier
    Verpillat, Patrice
    Sorensen, Henrik T.
    Cronin-Fenton, Deirdre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 442 - 443
  • [25] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [26] Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
    Mallett, Grace
    Laurence, Arian
    Amarnath, Shoba
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [27] Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
    Momtaz, Parisa
    Postow, Michael A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 357 - 365
  • [28] Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
    Pawlowska, Anna
    Suszczyk, Dorota
    Tarkowski, Rafal
    Paduch, Roman
    Kotarski, Jan
    Wertel, Iwona
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 9691 - 9709
  • [29] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    MODERN PATHOLOGY, 2017, 30 : 344A - 344A
  • [30] Programmed Death-1 (PD-1) Receptor/PD-1 Ligand (PD-L1) Expression in Fumarate Hydratase-Deficient Renal Cell Carcinoma
    Alaghehbandan, Reza
    Stehlik, Jan
    Trpkov, Kiril
    Magi-Galluzzi, Cristina
    Foix, Maria Pane
    Berney, Daniel
    Sibony, Mathilde
    Suster, Saul
    Agaimy, Abbas
    Montiel, Delia Perez
    Pivovarcikova, Kristyna
    Michalova, Kvetoslava
    Daum, Ondrej
    Ondic, Ondrej
    Rotterova, Pavla
    Michal, Michal
    Hes, Ondrej
    LABORATORY INVESTIGATION, 2017, 97 : 211A - 211A
12345